We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 19 JULY 2013
Myriad’s Effect On Drafting "Gene Patents"
Nutter McClennen & Fish LLP
In a highly anticipated decision issued on June 13, 2013 in Ass’n for Molecular Pathology v. Myriad, the U.S. Supreme Court unanimously ruled that isolated DNA sequences are not eligible for patent protection.
United StatesIntellectual Property






